

October 2024

Table 3: HBV Vaccine Dosing Schedule		
Vaccine	Dosing	Notes
Hepelisav-B [a]	<p>Single dose: 20 µg as one 0.5 mL dose containing 20 µg/mL vaccine administered as follows:</p> <ul style="list-style-type: none"> • 2 IM injections at weeks 0 and 4 	<ul style="list-style-type: none"> • Patients with ESRD: Standard dosing [Awad, et al. 2021] • Pregnant patients: Insufficient data to recommend use
Engerix-B	<p>Single dose: 20 µg as one 1 mL dose containing 20 µg/mL vaccine administered as follows:</p> <ul style="list-style-type: none"> • 3 IM injections at weeks 0, 4, and 24 OR • 4 IM injections at weeks 0, 4, 8, and 24 <p>Double dose: 40 µg as two 1 mL doses of 20 µg/mL vaccine administered as follows:</p> <ul style="list-style-type: none"> • 3 IM injections at weeks 0, 4, and 24 OR • 4 IM injections at weeks 0, 4, 8, and 24 	<p>Patients with ESRD or other immunocompromising conditions [b]: 40 µg/mL as two 1 mL doses of 20 µg/mL vaccine administered in 3 IM injections at weeks 0, 4, 8, and 24</p>
Recombivax HB	<p>Single dose: 10 µg as one 1 mL dose containing 10 µg/mL vaccine administered as follows:</p> <ul style="list-style-type: none"> • 3 IM injections at weeks 0, 4, and 24 OR • 4 IM injections at weeks 0, 4, 8, and 24 <p>Double dose [c]: 20 µg as two 1 mL doses containing 10 µg/mL vaccine administered as follows:</p> <ul style="list-style-type: none"> • 3 IM injections at weeks 0, 4, and 24 OR • 4 IM injections at weeks 0, 4, 8, and 24 	<p>Patients with ESRD or other immunocompromising conditions [b]: 40 µg/mL as 1 mL of higher-strength vaccine administered in 4 IM injections at weeks 0, 4, and 24</p>
Twinrix [d]	<p>Single dose: 1 mL administered as follows:</p> <ul style="list-style-type: none"> • 3 IM injections at weeks 0, 4, and 24 	<p>For patients who are not immune to either HBV or HAV</p>
<p>Abbreviations: ESRD, end-stage renal disease; HAV, hepatitis A virus; HBV, hepatitis B virus; IM, intramuscular.</p> <p>Notes:</p> <p>a. Double dosing and an accelerated schedule with Hepelisav-B have not been well studied.</p> <p>b. Higher-strength regimens of both Engerix-B and Recombivax HB are approved by the U.S. Food and Drug Administration for use in patients with ESRD; these higher-strength regimens may also be considered for patients with other immunocompromising conditions.</p> <p>c. Double dosing with Recombivax HB has not been as well studied as double dosing with Engerix-B. However, Recombivax HB may be the only formulation available at some institutions.</p> <p>d. Double dosing and use of a 4-dose series with Twinrix have not been well studied in patients with HIV and are not recommended.</p>		

Reference

Awad AM, Ntoso A, Connaire JJ, et al. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. *Vaccine* 2021;39(25):3346-52. [PMID: 34001345] <https://pubmed.ncbi.nlm.nih.gov/34001345>